News coverage about Bristol-Myers Squibb Company (NYSE:BMY) has been trending positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bristol-Myers Squibb Company earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 84 out of 100, meaning that recent press coverage is very likely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Bristol-Myers Squibb Company (NYSE:BMY) Position Increased by Shayne & CO. LLC (eleganthomesinla.com)
- Wealth Architects LLC Increases Stake in Bristol-Myers Squibb Company (NYSE:BMY) (theaviationweek.net)
- Is Bristol-Myers Squibb Company (BMY) a good buy? – Leicester Post (leicesterpost.com)
- Financial Analysis and Stock Valuation: Bristol-Myers Squibb Company (BMY), NIKE, Inc. (NKE) – AllStockNews (allstocknews.com)
- BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers (form 8-K) (4-traders.com)
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 55.15 on Monday. The company has a 50-day moving average of $54.58 and a 200 day moving average of $55.03. The firm has a market capitalization of $90.86 billion, a PE ratio of 19.16 and a beta of 1.16. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $77.12.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/bristol-myers-squibb-company-nysebmy-given-news-sentiment-rating-of-0-31/1524937.html
Bristol-Myers Squibb Company (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.72 by $0.12. The company had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.75 billion. Bristol-Myers Squibb Company had a return on equity of 31.86% and a net margin of 24.22%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.74 earnings per share. On average, analysts predict that Bristol-Myers Squibb Company will post $2.95 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Wednesday, July 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.83%. Bristol-Myers Squibb Company’s payout ratio is 54.17%.
Several equities analysts recently commented on BMY shares. Vetr raised shares of Bristol-Myers Squibb Company from a “hold” rating to a “buy” rating and set a $61.64 price target for the company in a research report on Tuesday, March 21st. BMO Capital Markets lowered shares of Bristol-Myers Squibb Company from a “market perform” rating to an “underperform” rating and set a $47.00 price target for the company. in a research report on Wednesday, May 3rd. Robert W. Baird started coverage on shares of Bristol-Myers Squibb Company in a research report on Tuesday, April 25th. They set an “outperform” rating for the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb Company in a research report on Monday, June 5th. Finally, BidaskClub lowered shares of Bristol-Myers Squibb Company from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Bristol-Myers Squibb Company presently has a consensus rating of “Hold” and an average price target of $62.61.
ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (NYSE:BMY) Given News Sentiment Rating of 0.31” was originally published by Zolmax and is owned by of Zolmax. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://zolmax.com/investing/bristol-myers-squibb-company-nysebmy-given-news-sentiment-rating-of-0-31/1524937.html.
Bristol-Myers Squibb Company Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.